Not finding it? Sign in to also search OpenAlex live.
-
Abstract GS4-04: Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2- trial2021 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Nadia Harbeck, Oleg Gluz, Sherko Küemmel, Matthias Christgen, Michael S Braun, Bahriye Aktas, +21 more
12citations -
ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer (EBC).
Nadia Harbeck, Oleg Gluz, Matthias Christgen, Monika Graeser, Felix Hilpert, Katja Krauss, +11 more
18citations -
Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy2020 Clinical Cancer Research article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access cited by 1 patent
Iris Noordhoek, Kai Treuner, Hein Putter, Yi Zhang, Jenna Wong, Elma Meershoek‐Klein Kranenbarg, +4 more
133citations -
Data from Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy
Iris Noordhoek, Kai Treuner, Hein Putter, Yi Zhang, Elma Meershoek‐Klein Kranenbarg, Marjolijn Duijm‐de Carpentier, +3 more
0citations -
Breast cancer index (BCI) predicts benefit of two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the ideal trial.2020 Journal of Clinical Oncology conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Gerrit‐Jan Liefers, Iris Noordhoek, Kai Treuner, Hein Putter, Yi Zhang, Elma Meershoek‐Klein Kranenbarg, +3 more
4citations -
Abstract PD6-11: PD6-11 Evaluation of the Sensitivity to Endocrine Therapy Index (SET2,3) in Early Male Breast Cancer: Results from an analysis in the EORTC 10085/TBCRC/BIG/NCTN International Male Breast Cancer Program
Danielle Brandes Zakon, Coralie Poncet, Fátima Cardoso, Neven Anouk, Vicente Valero, Stefan Paul Aebi, +28 more
0citations -
Abstract OT1-04-02: POSITIVE: A study evaluating pregnancy, disease outcome and safety of interrupting endocrine therapy for premenopausal women with endocrine responsive breast cancer who desire pregnancy (IBCSG 48-14/big 8-13)2020 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Olivia Pagani, Ann H. Partridge, Fedro Alessandro Peccatori, Hatem A. Azim, Chikako Shimizu, Cristina Saura, +5 more
0citations -
Abstract PD15-04: Breast Cancer Index and assessment of the Net Treatment Benefit (NTB) of extended endocrine therapy in HR+ breast cancer2022 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Marc E Buyse, Jenna Wong, Samuel Salvaggio, Jean‐Christophe Chiêm, Yi Zhang, Kai Treuner, +4 more
0citations -
Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy2024 JAMA Network Open article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access cited by 1 patent
Laura van ‘t Veer, Elma Meershoek‐Klein Kranenbarg, Marjolijn Duijm‐de Carpentier, Cornelis J. H. van de Velde, Miranda Kleijn, Christa Dreezen, +3 more
12citations -
Breast Cancer Index and prediction of benefit from extended endocrine therapy based on treatment compliance: An IDEAL study.2021 Journal of Clinical Oncology conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Gerrit‐Jan Liefers, Iris Noordhoek, Kai Treuner, Hein Putter, Jenna Wong, Yi Zhang, +3 more
0citations -
18F-Fluoroestradiol PET/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor–Positive Breast Cancer: A Systematic Review and Metaanalysis2025 Journal of Nuclear Medicine review Medicine Medical Imaging Techniques and Applications Open access
Ashwin Singh Parihar, Sofia Carrilho Vaz, Siobhan Sutcliffe, Niharika Pant, Jan W. Schoones, Gary A. Ulaner
8citations -
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer2023 New England Journal of Medicine article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Ann H. Partridge, Samuel M. Niman, Monica Ruggeri, Fedro Alessandro Peccatori, Hatem A. Azim, Marco Angelo Colleoni, +32 more
229citations -
Neoadjuvant endocrine therapy often leads to breast and axilla‐conserving surgery in stages II and III hormone receptor‐positive breast cancer patients: A registry study2025 International Journal of Cancer article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Layla Andour, Judith R. Kroep, Hein Putter, Rob A.�E.�M. Tollenaar, Wilma E. Mesker, Marieke Evelien Straver
4citations -
Side-effects in women treated with adjuvant endocrine therapy for breast cancer2025 The Breast article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Roxanne Gal, Anne Maria May, Marilot C. T. Batenburg, Femke van der Leij, Rhodé M. Bijlsma, Helena Marieke Verkooijen, +5 more
12citations -
Abstract GS5-10: Utility of the 70-gene MammaPrint test for prediction of extended endocrine therapy benefit in patients with early-stage breast cancer in the IDEAL Trial2023 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Gerrit‐Jan Liefers, Elma Meershoek‐Klein Kranenbarg, Marjolijn Duijm‐de Carpentier, Cornelis J.�H. van de Velde, Miranda Kleijn, Christa Dreezen, +3 more
9citations -
The Predictive Value of the Tumor‐Stroma Ratio for Neoadjuvant Endocrine Therapy in Hormone Receptor‐Positive Breast Cancer2026 International Journal of Cancer article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Layla Andour, Sophie C. Hagenaars, Anne Florine de Groot, Elly MM Krol-Warmerdam, Judith R. Kroep, Hans Marten Hazelbag, +3 more
1citations -
Abstract GS4-09: Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14/BIG 8-13)2023 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Ann Partridge, Olivia Pagani, Samuel M. Niman, Monica Ruggeri, Fedro Alessandro Peccatori, Hatem A. Azim, +30 more
9citations -
Abstract P2-03-13: Breast Cancer Index (BCI) identifies fewer patients with high risk of late recurrence and high likelihood of benefit from extended endocrine therapy with invasive lobular compared to invasive ductal carcinoma2023 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Otto Metzger, Neeta Parimi, Natalia Siuliukina, Yi Zhang, Kai Treuner, Gerrit‐Jan Liefers
3citations -
Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial2023 EClinicalMedicine article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Vivianne C. G. Tjan‐Heijnen, Senna W. M. Lammers, Sandra M. E. Geurts, Ingeborg J. H. Vriens, Astrid C P Swinkels, Carolien H. Smorenburg, +8 more
16citations